Innovation is in GenSci's DNA. GenSci advances a robust, innovative portfolio across four therapeutic areas: endocrinology & metabolism, women's health, immunology & respiratory diseases, and oncology.
Guided by global R&D strategy, besides robust research engines, we execute Multi-Regional Clinical Trials (MRCT) with high efficiency and high standards in China and overseas. Our innovation engine is powered by cutting-edge technology platforms, enhanced by AI to enable precision-targeting therapeutic development.
Concurrently, we are building a global R&D network to foster worldwide collaboration. This network is crucial for accelerating our research and development of innovative medicines and ensures our research outcomes finely calibrated to address the complex and diverse needs of global markets.
-
40+
Clinical Pipeline
-
6
Multi-Regional Clinical Trials
-
26.5%
R&D investment as a percentage of sales revenue in 2025
-
80+
Held Patents；
Pending Applications: 279；
International Patents Submitted: 56
R&D Highlight
We leverage cutting-edge technologies to accelerate drug discovery and build differentiated pipelines targeting major diseases.
-
AI-EmpoweredLeverage AI to speed drug discovery and development
AI-EmpoweredLeverage AI to speed drug discovery and development
-
Top TechnologyDevelop differentiated and leading platforms
Top TechnologyDevelop differentiated and leading platforms
-
Unmet NeedsFocus on therapeutic areas with clinical unmet needs
Unmet NeedsFocus on therapeutic areas with clinical unmet needs
-
Large InvestmentInvest significantly in R&D
Large InvestmentInvest significantly in R&D
-
Global CooperationTeam up with innovators worldwide
Global CooperationTeam up with innovators worldwide
